Abcam, ab263925, Human THY1 (CD90) knockout U-2 OS cell lysate

Size: 1Kit
THY1 KO cell lysate available now. KO validated by Next Generation Sequencing, Western blot. Free of charge wild type control included.
Key facts
Cell type:U-2 OS,
Species or organism:Human,
Tissue:Bone,
Knockout validation:Next Generation Sequencing,Western blot,
Disease:Osteosarcoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-THY1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Next Generation Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
CD90 also known as Thy1 is a glycoprotein with a molecular mass of approximately 25-37 kDa. It is highly conserved across species and found on the surface of various cell types including fibroblasts neurons and endothelial cells. CD90 is expressed in these cells in tissues such as the brain thymus and lungs. Researchers use anti-CD90 antibodies for detection often in combination with CD90 FITC in immunofluorescence assays. CD90 serves as a useful cell marker particularly in identifying mesenchymal stem cells (MSCs).
Biological function summary
CD90 plays a role in cell-cell and cell-matrix interactions contributing to cellular adhesion migration and signal transduction. It functions as part of a complex involving integrins which mediate its interaction with the extracellular matrix. This protein also influences T-cell activation reflecting its importance in immune response regulation. Its presence aids in modulating response to injury and promoting tissue repair due to its association with stem and progenitor cells.
Pathways
CD90 engagement affects focal adhesion and MAPK signaling pathways. It interacts with integrins like αvβ3 and α5β1 influencing cell movement and proliferation processes. CD90 involvement in these pathways allows it to regulate responses important for cell survival and communication within various tissues. These interactions highlight the protein's role in maintaining cellular homeostasis and regulating physiological processes.
CD90 has associations with fibrosis and cancer. In fibrotic conditions CD90 expression affects fibroblast activity influencing tissue scarring in organs such as the liver and lungs. In cancer CD90 modifies tumor progression and metastasis by impacting cell adhesion and migration with connections to proteins like TGF-beta which further drive these processes. Understanding CD90 in disease contexts facilitates the development of therapeutic strategies aimed at modulating its activity.